FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Introduction The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi’s (NASDAQ:SNY) hemophilia therapy, Qfitlia, marking a significant advancement in treatment options for patients ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Donald Trump's presidential approval ratings appear immune to the somewhat chaotic start to his second term and the most recent onslaught of tariffs and trade wars — hitting his all-time high ...

OMRIX Biopharmaceuticals, Inc. ( Omrix or the Company ) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products ...

British journalist and translator who joined Diario AS in 2013. Focuses on soccer – chiefly the Premier League, LaLiga, the Champions League, the Liga MX and MLS. On occasion, also covers ...

Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.